Advances in the treatment of diabetic renal disease: focus on losartan

References

• US renal data system. USRDS 1999 annual data report. Bethesda MD: National Institute of Diabetes and Digestive and Kidney Disease 1999
   Google Scholar
• Valderrabano F, Berthoux FC, Jones EH, Mehls O. Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association. Nephrol Dial Transplant 1996;11(Suppl 1):2–21
   Google Scholar
• Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001;12:2753–8
   PubMed Web of Science ®Google Scholar
• Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225–32
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diabetic Nephropathy. Diabetes Care 2003;26 (Suppl 1), S94–S98
   PubMedGoogle Scholar
• Abdi R, Brenner BM. The nephropathy of type 2 diabetes: introduction. In: Mogensen CE, ed. Diabetic nephropathy in type 2 diabetes. London: Science Press Ltd, 2003;1–4
   Google Scholar
• European Society of Hypertension Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011–53
   Google Scholar
• Hollenberg NK, Osei SY, Lansang MC, Price DA, Fisher ND. Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man. J Renin Angiotensin Aldosterone Syst 2001;2:14–8
   Google Scholar
• Osei SY, Price DA, Laffel LM, Lansang MC, Hollenberg NK. Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin–angiotensin system in healthy humans. Hypertension 2000;36:122–6
   Google Scholar
• Williams B. The renin–angiotensin system and the pathogenesis of diabetic nephropathy. In: Mogensen CE, ed. Diabetic nephropathy in type 2 diabetes. Science Press, 2003:57–70
   Google Scholar
• Blantz RC, Gabbai FB. Effect of angiotensin II on glomerular hemodynamics and ultrafiltration coefficient. Kidney Int Suppl 1987;20:S108–S111
   PubMedGoogle Scholar
• Gilbert RE, Cox A, Wu LL et al. Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 1998;47:414–22
   PubMed Web of Science ®Google Scholar
• Jaimes EA, Galceran JM, Raij L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998;54:775–84
   Google Scholar
• Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359–64
   PubMed Web of Science ®Google Scholar
• Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73–87
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456–62
   PubMed Web of Science ®Google Scholar
• Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994;271:275–9
   PubMed Web of Science ®Google Scholar
• Remuzzi A, Perico N, Amuchastegui CS et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993;4:40–9
   PubMed Web of Science ®Google Scholar
• Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992;90:766–71
   PubMed Web of Science ®Google Scholar
• Holdaas H, Hartmann A, Berg KJ, Lund K, Fauchald P. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant 1998;13:3096–102
   PubMed Web of Science ®Google Scholar
• Toto R, Shultz P, Raij L et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension 1998;31:684–91
   PubMed Web of Science ®Google Scholar
• Praga M, Andrade CF, Luño J et al. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant 2003;18:1–8
   Google Scholar
• Park HC, Xu ZG, Choi S et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-β1 in patients with IgA nephropathy. Nephrol Dial Transplant 2003;18:1115–21
   PubMed Web of Science ®Google Scholar
• Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57: 601–6
   Google Scholar
• Zandbergen AA, Baggen MG, Lamberts SW, Bootsma AH, de Zeeuw D, Ouwendijk RJ. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Ann Intern Med 2003;139:90–6
   PubMed Web of Science ®Google Scholar
• Chan JC, Critchley JA, Tomlinson B, Chan TY, Cockram CS. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997;17:72–80
   Google Scholar
• Lozano JV, Llisterri JL, Aznar J, Redon J. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001;16(Suppl 1):85–9
   PubMedGoogle Scholar
• Esmatjes E, Flores L, Iñigo P, Lario S, Ruilope LM, Campistol JM. Effect of losartan on TGF-β1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 2001;16\(Suppl 1):90–3
   Google Scholar
• Lacourcière Y, Bélanger A, Godin C et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000;58:762–9
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–9
   Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004–10
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Dahlof B, Edelman JM et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003;362:619–20
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002;20:1879–86
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–9
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345: 870–8
   Google Scholar
• Zanella M-T, Ribeiro AB. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. Clin Ther 2002;24: 1019–34
   Google Scholar
• Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440–4
   PubMed Web of Science ®Google Scholar
• Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117–24
   PubMed Web of Science ®Google Scholar
• Doggrell SA. Class benefits of AT1 anatgonists in type 2 diabetes with nephropathy. Expert Opin Pharmacother 2002;3:625–8
   PubMedGoogle Scholar
• Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672–8
   PubMed Web of Science ®Google Scholar
• Sharma K, Eltayeb BO, McGowan TA et al. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999;34:818–23
   PubMed Web of Science ®Google Scholar
• Krämer C, Sunkomat J, Witte J et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002;90:770–6
   PubMed Web of Science ®Google Scholar
• Appel GB, Radhakrishnan J, Avram MM et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003;26:1402–7
   PubMed Web of Science ®Google Scholar
• Chlopicki S, Koda M, Chabielska E, Buczko W, Gryglewski RJ. Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition. J Physiol Pharmacol 2000;51: 715–22
   Google Scholar
• Li P, Ferrario CM, Brosnihan KB. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1998;32: 198–205
   Google Scholar
• Jiménez AM, Montón M, García R et al. Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. J Cardiovasc Pharmacol 2001;37:406–12
   PubMed Web of Science ®Google Scholar
• Montón M, Jiménez A, Núñez A et al. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol 2000;35:906–13
   PubMed Web of Science ®Google Scholar
• Núñez A, Gómez J, Zalba LR et al. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst 2000;1:175–9
   PubMedGoogle Scholar
• Guerra-Cuesta JI, Montón M, Rodríguez-Feo JA et al. Effect of losartan on human platelet activation. J Hypertens 1999;17:447–52
   PubMed Web of Science ®Google Scholar
• Krämer C, Sunkomat J, Witte J et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002;90:770–6
   PubMed Web of Science ®Google Scholar
• Levy PJ, Yunis C, Owen J, Brosnihan KB, Smith R, Ferrario CM. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000;86:1188–92
   PubMed Web of Science ®Google Scholar
• Moser L, Callahan KS, Cheung AK, Stoddard GJ, Munger MA. ACE inhibitor effects on platelet function in stages I-II hypertension. J Cardiovasc Pharmacol 1997;30:461–7
   Google Scholar
• Kang DH, Nakagawa T, Feng L et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888–97
   PubMed Web of Science ®Google Scholar
• Wurzner G, Gerster JC, Chiolero A et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001;19:1855–60
   PubMed Web of Science ®Google Scholar
• Ilson BE, Martin DE, Boike SC, Jorkasky DK. The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J Clin Pharmacol 1998;38:437–41
   PubMed Web of Science ®Google Scholar